Clinical Trials Logo

Alport Syndrome clinical trials

View clinical trials related to Alport Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03749447 Terminated - Clinical trials for Chronic Kidney Diseases

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

EAGLE
Start date: March 8, 2019
Phase: Phase 3
Study type: Interventional

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

NCT ID: NCT02855268 Terminated - Alport Syndrome Clinical Trials

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

HERA
Start date: November 2, 2019
Phase: Phase 2
Study type: Interventional

Primary Objectives: - To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function. - To assess the safety and tolerability of lademirsen (SAR339375) in participants with Alport syndrome. Secondary Objectives: - To assess plasma pharmacokinetic (PK) parameters of the parent compound and its active major metabolite. - To assess the potential formation of anti-drug antibodies (ADAs) following administration of lademirsen (SAR339375). - To assess the pharmacodynamic effect of lademirsen (SAR339375) on miR-21 and on changes in renal injury and function biomarkers.

NCT ID: NCT01602835 Terminated - Alport Syndrome Clinical Trials

Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Start date: September 2012
Phase: N/A
Study type: Observational

This is a prospective cross-sectional, observational, single-center study of Alport patients, in which a single, first morning voided urine collection will be acquired and used to validate assays of urine biomarkers that reflect changes in glomerular protein filtration barrier function. The purpose of this study is to identify biomarkers indicative of changes in glomerular filtration function that occur during the course of proteinuric renal diseases such as Alport nephropathy.